チグリタザール/メトホルミン徐放錠のパイロット生物学的同等性試験
健康な被験者におけるChiglitazar/メトホルミン徐放性配合錠のパイロットバイオ等価性試験:食事条件下での無作為化、オープンラベル、2期間、単回投与、クロスオーバー試験
This is a pilot bioequivalence study. It is a randomized, open-label, single-dose, crossover study. The primary objective of this study is to preliminarily evaluate the pharmacokinetic parameters and their variability of the test formulation versus the reference formulation following a single oral dose under fed conditions.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Hunan
-
Yueyang、Hunan、中国、414000
- Hunan Institute of Schistosomiasis Control (Hunan Provincial Third People's Hospital)
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Healthy male or female participants;
- Age from 18 to 45 years, inclusive;
- Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive). Male participants must weigh at least 50.0 kg, and female participants must weigh at least 45.0 kg;
- From the time of signing the informed consent form until 3 months after the last dose, participants must have no plans for pregnancy or sperm donation and must be willing to use effective contraceptive measures;
- Voluntarily agrees to participate in the study and signs the informed consent form.
Exclusion Criteria:
- Any clinically significant abnormalities in laboratory tests or a history of clinically significant diseases, including but not limited to cardiovascular, cerebrovascular, hepatic, renal, respiratory, gastrointestinal, neurological, hematological, immune, oncological, psychiatric, or endocrine/metabolic disorders;
- Known history of severe allergies (e.g., allergy to more than 3 allergens, allergies affecting the lower respiratory tract such as allergic asthma, allergies requiring glucocorticoid treatment) or a known history of allergy to any component of the investigational products;
- Previous surgery that could affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or a history of gastrointestinal, hepatic, or renal disease within the last 6 months that could affect drug absorption or metabolism;
- Surgery within 3 months prior to screening or planned surgery during the study period;
- Received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period;
- History of infectious disease treated with significant use of antibiotics within 3 months before the first dose, or any infectious disease within 7 days before the first dose;
- Presence of gastrointestinal symptoms (e.g., diarrhea, constipation, nausea, vomiting) within 7 days before the first dose, which the investigator deems unsuitable for study participation;
- Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before the first dose; or use of vitamin products within 2 weeks before enrollment;
- History of drug or substance abuse, or a positive alcohol or urine drug screening test;
- Intolerance to venipuncture, or a history of fainting in response to needles or blood;
- Fasting blood glucose > 6.1 mmol/L or < 3.9 mmol/L at screening, and/or a history of hypoglycemia/syncope;
- Participation in any interventional clinical trial within 3 months prior to screening;
- Blood donation or significant blood loss (> 200 mL) within 3 months prior to screening;
- Pregnant or lactating women;
- Weekly alcohol consumption of more than 14 units within 3 months prior to screening, consumption of alcohol within 48 hours before the first dose, or inability to abstain from alcohol during the study;
- Smokes more than 5 cigarettes per day within 3 months prior to screening, has smoked within 48 hours before the first dose, or is unable to abstain from smoking during the study;
- Excessive daily consumption of tea, coffee, and/or caffeinated beverages within 3 months prior to screening, or consumption of such beverages within 48 hours before the first dose;
- Consumption of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), star fruit, papaya, pomegranate, or their products within 14 days before the first dose;
- Glomerular Filtration Rate (GFR) < 90 mL/min/1.73 m²;
- Systolic blood pressure < 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure < 60 mmHg or ≥ 90 mmHg at screening;
- A positive test result at screening for any of the following: Human Immunodeficiency Virus antibody, Treponema pallidum antibody, Hepatitis B surface antigen, or Hepatitis C virus antibody;
- Inability to comply with the standardized diet (e.g., intolerance to the high-fat meal, lactose intolerance) or has difficulty swallowing;
- Plans to or is required to engage in strenuous physical activity or exercise during the study period;
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Treatment Sequence T-R (dose 1)
Participants will receive treatment T (Chiglitazar/Metformin extended-release fixed dose combination tablets) on Day 1 followed by treatment R (Chiglitazar tablets and Metformin extended-release tablets) on Day 8. |
Chiglitazar/Metformin extended-release fixed dose combination tablets (dose 1) Chiglitazar tablets and Metformin extended release tablets (dose 1) |
|
実験的:Treatment Sequence R-T (dose 1)
Participants will receive treatment R (Chiglitazar tablets and Metformin extended-release tablets) on Day 1 followed by treatment T (Chiglitazar/Metformin extended-release fixed dose combination tablets) on Day 8. |
Chiglitazar/Metformin extended-release fixed dose combination tablets (dose 1) Chiglitazar tablets and Metformin extended release tablets (dose 1) |
|
実験的:Treatment Sequence T-R (dose 2)
Participants will receive treatment T (Chiglitazar/Metformin extended-release fixed dose combination tablets) on Day 1 followed by treatment R (Chiglitazar tablets and Metformin extended-release tablets) on Day 8. |
Chiglitazar/Metformin extended-release fixed dose combination tablets (dose 2) Chiglitazar tablets and Metformin extended release tablets (dose 2) |
|
実験的:Treatment Sequence R-T (dose 2)
Participants will receive treatment R (Chiglitazar tablets and Metformin extended-release tablets) on Day 1 followed by treatment T (Chiglitazar/Metformin extended-release fixed dose combination tablets) on Day 8. |
Chiglitazar/Metformin extended-release fixed dose combination tablets (dose 2) Chiglitazar tablets and Metformin extended release tablets (dose 2) |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
最高血中濃度(Cmax)
時間枠:投与前および投与後最大72時間までの複数の時点
|
投与前および投与後最大72時間までの複数の時点
|
|
血漿中濃度-時間曲線下面積(0時から最終測定濃度まで)(AUC0-last)
時間枠:投与前および投与後最大72時間までの複数の時間点
|
投与前および投与後最大72時間までの複数の時間点
|
|
時間ゼロから無限大までの血漿中濃度-時間曲線下面積(AUC0-∞)
時間枠:投与前および投与後72時間までの複数の時点で
|
投与前および投与後72時間までの複数の時点で
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
最大血漿中濃度到達時間(Tmax)
時間枠:投与前および投与後72時間までの複数の時点で
|
投与前および投与後72時間までの複数の時点で
|
|
消失半減期(t1/2)
時間枠:投与前および投与後最大72時間までの複数の時点
|
投与前および投与後最大72時間までの複数の時点
|
|
見かけの総クリアランス(CL/F)
時間枠:投与前および投与後最大72時間までの複数の時間点
|
投与前および投与後最大72時間までの複数の時間点
|
|
終末相における見かけの分布容積(Vz/F)
時間枠:投与前および投与後72時間までの複数の時点で
|
投与前および投与後72時間までの複数の時点で
|
|
安全性評価:有害事象(AE)の発生率
時間枠:Day 13まで
|
Day 13まで
|
|
ベースラインからの臨床検査安全性パラメーターの変化(血液学、血清生化学、凝固検査、尿検査を含む)
時間枠:Day 11まで
|
Day 11まで
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- CGZ113
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。